Shares of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) saw unusually-strong trading volume on Thursday . Approximately 1,122,700 shares traded hands during mid-day trading, an increase of 128% from the previous session’s volume of 493,487 shares.The stock last traded at $2.32 and had previously closed at $2.12.
Several analysts recently weighed in on EYPT shares. HC Wainwright set a $3.00 price objective on shares of Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Zacks Investment Research cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 4th. Finally, ValuEngine raised shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 29th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $4.90.
The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 1.57. The company has a market capitalization of $125.35 million, a price-to-earnings ratio of -4.27 and a beta of 0.97.
A number of institutional investors and hedge funds have recently modified their holdings of EYPT. FineMark National Bank & Trust bought a new stake in Eyepoint Pharmaceuticals during the second quarter valued at $118,000. California Public Employees Retirement System bought a new stake in Eyepoint Pharmaceuticals during the second quarter valued at $135,000. Creative Planning bought a new stake in Eyepoint Pharmaceuticals during the second quarter valued at $162,000. Essex Investment Management Co. LLC bought a new stake in Eyepoint Pharmaceuticals during the second quarter valued at $170,000. Finally, Bard Associates Inc. bought a new stake in Eyepoint Pharmaceuticals during the second quarter valued at $189,000. 62.93% of the stock is currently owned by institutional investors and hedge funds.
Eyepoint Pharmaceuticals Company Profile (NASDAQ:EYPT)
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
See Also: Dividend
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.